Who are A arm (CLAG-M)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prednisone, Dexamethasone, Vincristine, Daunorubicin, PAx5/PCMx5, PACx14, Course B1 +Vin, Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Modified HIT-SKK Cycle B4-5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/a-arm-clag-m.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

A arm (CLAG-M) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A arm (CLAG-M) (A arm (CLAG-M)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-agent chemotherapy regimen. Area: Oncology.

phase 3 Multi-agent chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

A arm (CLAG-M) (A arm (CLAG-M)) — Polish Adult Leukemia Group. CLAG-M is a chemotherapy regimen combining cladribine, cytarabine, and mitoxantrone designed to induce remission in acute myeloid leukemia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
A arm (CLAG-M) TARGET	A arm (CLAG-M)	Polish Adult Leukemia Group	phase 3	Multi-agent chemotherapy regimen
Prednisone, Dexamethasone, Vincristine, Daunorubicin	Prednisone, Dexamethasone, Vincristine, Daunorubicin	St. Jude Children's Research Hospital	phase 3	Multi-agent chemotherapy regimen
PAx5/PCMx5	PAx5/PCMx5	SWOG Cancer Research Network	phase 3	Multi-agent chemotherapy regimen
PACx14	PACx14	SWOG Cancer Research Network	phase 3	Multi-agent chemotherapy regimen
Course B1 +Vin	Course B1 +Vin	Children's Cancer Group, China	phase 3	Multi-agent chemotherapy regimen
Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan	Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan	Dutch Childhood Oncology Group	phase 3	Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor
Modified HIT-SKK Cycle B4-5	Modified HIT-SKK Cycle B4-5	Nationwide Children's Hospital	phase 3	Multi-agent chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-agent chemotherapy regimen class)

St. Jude Children's Research Hospital · 3 drugs in this class
Nationwide Children's Hospital · 2 drugs in this class
SWOG Cancer Research Network · 2 drugs in this class
Children's Cancer Group, China · 1 drug in this class
Gruppo Italiano Studio Linfomi · 1 drug in this class
Polish Adult Leukemia Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A arm (CLAG-M) — Competitive Intelligence Brief. https://druglandscape.com/ci/a-arm-clag-m. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing